# Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada

- Link: https://www.thailand-business-news.com/pr-news/septa-pharmaceuticals-inc-acquires-ceenu-lomustine-from-bristol-myers-squibb-canada
- Published: 2026-07-15T18:00:00+07:00
- Author: PR Newswire

MISSISSAUGA, ON, July 15, 2026 /PRNewswire/ — [Septa Pharmaceuticals Inc.](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4730709-1&h=214253588&u=https%3A%2F%2Fseptalife.com%2F&a=Septa+Pharmaceuticals+Inc.),
a rapidly growing leader in the Canadian healthcare sector, is proud to announce
the successful acquisition of [CeeNU^(®)](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4730709-1&h=2667387860&u=http%3A%2F%2Fwww.myceenu.com%2F&a=CeeNU%C2%AE)(
Lomustine) from Bristol Myers Squibb, Canada as of June 29th, 2026. This strategic
acquisition marks a significant milestone in Septa’s ongoing expansion and underscores
its unwavering dedication to strengthening its specialty oncology pharmaceutical
portfolio. [CeeNU^(®)](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4730709-1&h=2667387860&u=http%3A%2F%2Fwww.myceenu.com%2F&a=CeeNU%C2%AE)(
Lomustine) is an established and highly valued alkylating agent utilized primarily
in the treatment of specific types of brain tumors and Hodgkin’s lymphoma. By integrating
this essential chemotherapy medication into its product lineup, Septa is reinforcing
its footprint in the critical care and oncology space.

 [⌊Septa and CeeNU Logo (CNW Group/Septa Pharmaceuticals Inc.)⌉](https://mma.prnasia.com/media2/3005802/Septa_Pharmaceuticals_Inc__Septa_Pharmaceuticals_Inc__Acquires_C.jpg?p=medium600)

Septa and CeeNU Logo (CNW Group/Septa Pharmaceuticals Inc.)

[CeeNU^(®)](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4730709-1&h=2667387860&u=http%3A%2F%2Fwww.myceenu.com%2F&a=CeeNU%C2%AE)(
Lomustine) represents an important therapeutic option for many individuals battling
severe health conditions. Consequently, Septa is deeply committed to ensuring continuous,
uninterrupted patient access to this vital medication across Canada. Recognizing
the critical need for a robust and stable supply of essential medicines in today’s
complex healthcare landscape, Septa is fiercely prioritizing the long-term availability
of [CeeNU^(®)](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4730709-1&h=2667387860&u=http%3A%2F%2Fwww.myceenu.com%2F&a=CeeNU%C2%AE)(
Lomustine).

"As we integrate [CeeNU^(®)](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4730709-1&h=2667387860&u=http%3A%2F%2Fwww.myceenu.com%2F&a=CeeNU%C2%AE)(
Lomustine) into our growing portfolio, our primary focus remains firmly on the patients
and the medical professionals who treat them," said Devinder K., President & CEO
of [Septa Pharmaceuticals Inc.](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4730709-1&h=2141602720&u=http%3A%2F%2Fwww.septalife.com%2F&a=Septa+Pharmaceuticals+Inc.)"
We are working collaboratively and closely with all relevant stakeholders, including
regulatory bodies and supply chain partners, to ensure a seamless transition. This
acquisition is a profound testament to our core mission of providing high-quality,
reliable pharmaceutical products that tangibly improve health outcomes both across
the country and globally."

As Septa rapidly broadens its diverse product portfolio and expands geographic territories,
the company is actively seeking new strategic partnerships and licensing opportunities.
We welcome collaborations with pharmaceutical companies to out/in-license, launch
and commercialize such high-impact therapies globally. Together, we can drive mutual
growth and ensure vital medicines reach global markets.

**About Septa Pharmaceuticals Inc.**

Headquartered in Ontario, Canada, [Septa Pharmaceuticals Inc.](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4730709-1&h=2141602720&u=http%3A%2F%2Fwww.septalife.com%2F&a=Septa+Pharmaceuticals+Inc.)
is a forward-thinking pharmaceutical company dedicated to the development, acquisition,
and commercialization of specialized pharmaceuticals globally. With a patient-first
philosophy, Septa consistently strives to bridge gaps in the healthcare market by
securing and stabilizing the supply of critical medicines. Through strategic partnerships
and targeted acquisitions, Septa continues to build a robust product pipeline and
managed access programs designed to meet the evolving needs of the global medical
community.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada ](http://www.prnasia.com/story/archive/5003589_AE03589_0?rand=184833)